Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 235
Filter
Add more filters

Country/Region as subject
Publication year range
1.
Ann Surg ; 2024 Jun 12.
Article in English | MEDLINE | ID: mdl-38864231

ABSTRACT

OBJECTIVE: This study sought to elucidate clinical and imaging findings predictive for malperfusion syndrome after blunt thoracic aortic injury (BTAI). SUMMARY BACKGROUND DATA: There is limited literature on malperfusion syndrome after BTAI and the timing of thoracic endovascular aortic repair (TEVAR) in patients with this condition has not been defined. METHODS: A retrospective analysis of prospectively collected data of patients with BTAI treated between January 2021 and October 2023. Clinical and thoracic aortic (TA) imaging data, time to TEVAR, in-hospital death, and malperfusion/reperfusion sequelae (paraplegia, renal/visceral/limb ischemia, and compartment syndromes) were assessed. Correlations between clinical and imaging findings, time to TEVAR, and outcomes were evaluated. RESULTS: Of the 19,203 trauma patients evaluated, 13,717 (71%) had blunt injuries and 77 (0.6%) had BTAI. The majority (67.5%) were male with a median age of 40 years (IQR:33-55). TEVAR was performed in 42 (54.5%) patients. Seven (9.1%) patients presented with clinical and TA imaging criteria for traumatic thoracic aortic coarctation (TTAC), including diminished/absent femoral pulses and TA luminal narrowing of 50-99%. The median time to TEVAR was 9 (IQR:5-32), 11, and 4 hours for all non-TTAC and TTAC BTAI patients, respectively (P=0.037). Only TTAC patients presented/developed malperfusion/reperfusion sequelae. In-hospital mortality rates were 7.8%, 5.8%, and 29% for all non-TTAC and TTAC BTAI patients, respectively (P=0.09). Aortic-related mortality occurred in only two (2.6%) TTAC patients.. CONCLUSIONS: Patients with clinical and TA imaging manifestations of TTAC are predisposed to malperfusion/reperfusion sequelae if TEVAR is delayed. We recommend the emergent repair of all BTAIs with TTAC.

2.
Ann Vasc Surg ; 84: 195-200, 2022 Aug.
Article in English | MEDLINE | ID: mdl-35247536

ABSTRACT

BACKGROUND: Blunt aortic injury (BAI) and traumatic brain injury (TBI) are the leading causes of death after blunt trauma. The purposes of this study were to identify predictors of mortality for BAI and to examine the impact of procedural heparinization during thoracic endovascular aortic repair (TEVAR) on neurologic outcomes in patients with BAI/TBI. METHODS: Patients with BAI were identified over an 8 year period. Age, gender, severity of injury and shock, time to TEVAR, morbidity, and mortality were recorded and compared. Multivariable logistic regression (MLR) was performed to determine independent predictors of mortality. Youden's index determined optimal time to TEVAR. RESULTS: A total of 129 patients were identified. The majority (74%) were male with a median age and injury severity score (ISS) of 40 years and 29, respectively. Of these, 26 (20%) had a concomitant TBI. Patients with BAI/TBI had higher injury burden at presentation (ISS 37 vs. 29, P = 0.002; Glasgow Coma Scale [GCS] 6 vs. 15, P < 0.0001), underwent fewer TEVAR procedures (31 vs. 53%, P = 0.039), and suffered increased mortality (39 vs. 16%, P = 0.009). All TEVARs had procedural anticoagulation, including patients with TBI, without change in neurologic function. The optimal time to TEVAR was 14.8 hr. Mortality increased in TEVAR patients before 14.8 hr (8.7 vs. 0%, P = 0.210). MLR identified TEVAR as the only modifiable factor that reduced mortality (odds ratio 0.11; 95% confidence interval 0.03-0.45, P = 0.002). CONCLUSIONS: TEVAR use was identified as the only modifiable predictor of reduced mortality in patients with BAI. Delayed TEVAR with the use of procedural heparin provides a safe option regardless of TBI with improved survival and no difference in discharge neurologic function.


Subject(s)
Aortic Diseases , Endovascular Procedures , Vascular System Injuries , Wounds, Nonpenetrating , Anticoagulants/adverse effects , Aorta, Thoracic/diagnostic imaging , Aorta, Thoracic/injuries , Aorta, Thoracic/surgery , Aortic Diseases/etiology , Endovascular Procedures/adverse effects , Female , Humans , Male , Retrospective Studies , Risk Factors , Treatment Outcome , Vascular System Injuries/complications , Vascular System Injuries/diagnostic imaging , Vascular System Injuries/surgery , Wounds, Nonpenetrating/complications , Wounds, Nonpenetrating/diagnostic imaging , Wounds, Nonpenetrating/surgery
3.
Clin Infect Dis ; 73(3): e710-e718, 2021 08 02.
Article in English | MEDLINE | ID: mdl-33720350

ABSTRACT

BACKGROUND: Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) are associated with high mortality rates. We evaluated the efficacy and safety of tedizolid (administered as tedizolid phosphate) for treatment of gram-positive ventilated HABP/VABP. METHODS: In this randomized, noninferiority, double-blind, double-dummy, global phase 3 trial, patients were randomized 1:1 to receive intravenous tedizolid phosphate 200 mg once daily for 7 days or intravenous linezolid 600 mg every 12 hours for 10 days. Treatment was 14 days in patients with concurrent gram-positive bacteremia. The primary efficacy end points were day 28 all-cause mortality (ACM; noninferiority margin, 10%) and investigator-assessed clinical response at test of cure (TOC; noninferiority margin, 12.5%) in the intention-to-treat population. RESULTS: Overall, 726 patients were randomized (tedizolid, n = 366; linezolid, n = 360). Baseline characteristics, including incidence of methicillin-resistant Staphylococcus aureus (31.3% overall), were well balanced. Tedizolid was noninferior to linezolid for day 28 ACM rate: 28.1% and 26.4%, respectively (difference, -1.8%; 95% confidence interval [CI]: -8.2 to 4.7). Noninferiority of tedizolid was not demonstrated for investigator-assessed clinical cure at TOC (tedizolid, 56.3% vs linezolid, 63.9%; difference, -7.6%; 97.5% CI: -15.7 to 0.5). In post hoc analyses, no single factor accounted for the difference in clinical response between treatment groups. Drug-related adverse events occurred in 8.1% and 11.9% of patients who received tedizolid and linezolid, respectively. CONCLUSIONS: Tedizolid was noninferior to linezolid for day 28 ACM in the treatment of gram-positive ventilated HABP/VABP. Noninferiority of tedizolid for investigator-assessed clinical response at TOC was not demonstrated. Both drugs were well tolerated. CLINICAL TRIALS REGISTRATION: NCT02019420.


Subject(s)
Methicillin-Resistant Staphylococcus aureus , Pneumonia, Bacterial , Skin Diseases, Bacterial , Anti-Bacterial Agents/adverse effects , Double-Blind Method , Hospitals , Humans , Linezolid/adverse effects , Organophosphates , Oxazoles , Pneumonia, Bacterial/drug therapy , Skin Diseases, Bacterial/drug therapy , Ventilators, Mechanical
4.
J Clin Pharm Ther ; 45(4): 836-839, 2020 Aug.
Article in English | MEDLINE | ID: mdl-32406951

ABSTRACT

WHAT IS KNOWN AND OBJECTIVE: Stenotrophomonas maltophilia is an intrinsically multidrug-resistant (MDR) organism which commonly presents as a respiratory tract infection. S. maltophilia is typically treated with high-dose sulfamethoxazole/trimethoprim (SMX/TMP). However, SMX/TMP and other treatment options for S. maltophilia can be limited because of resistance, allergy, adverse events or unavailability of the drug; use of novel agents may be necessary to adequately treat this MDR infection and overcome these limitations. CASE DESCRIPTION: This small case series describes two patients who underwent treatment with tigecycline for ventilator-associated pneumonia (VAP) caused by S. maltophilia after admission to a trauma intensive care unit. At the time of admission for the two reported patients, a national drug shortage of intravenous (IV) SMX/TMP prevented its use. Tigecycline was chosen as a novel agent to treat S. maltophilia VAP based on culture and susceptibility data, and it was used successfully. Both patients showed clinical signs of improvement with eventual cure and discharge from the hospital after treatment with tigecycline, and one patient demonstrated confirmed microbiological cure with a negative repeat bronchoscopic bronchoalveolar lavage (BAL). WHAT IS NEW AND CONCLUSION: To our knowledge, this small case series is the first documentation of utilizing tigecycline to treat S. maltophilia VAP in the United States. Although it likely should not be considered as a first-line agent, tigecycline proved to be an effective treatment option in the two cases described in the setting of a national drug shortage of the drug of choice.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Gram-Negative Bacterial Infections/drug therapy , Pneumonia, Ventilator-Associated/drug therapy , Stenotrophomonas maltophilia/drug effects , Tigecycline/therapeutic use , Adult , Humans , Intensive Care Units , Male , Trimethoprim, Sulfamethoxazole Drug Combination/supply & distribution , Trimethoprim, Sulfamethoxazole Drug Combination/therapeutic use , Wounds and Injuries/therapy
5.
Ann Pharmacother ; 52(2): 120-125, 2018 02.
Article in English | MEDLINE | ID: mdl-28906137

ABSTRACT

BACKGROUND: Achromobacter sp are nonfermenting Gram-negative bacilli (NFGNB) that rarely cause severe infections, including ventilator-associated pneumonia (VAP). Data on the treatment of Achromobacter pneumonia are very limited, and the organism has been associated with a high mortality rate. Thus, more data are needed on treating this organism. OBJECTIVE: To evaluate the treatment of Achromobacter VAP in critically ill trauma patients. METHODS: This retrospective, observational study evaluated critically ill trauma patients who developed Achromobacter VAP. A previously published pathway for the diagnosis and management of VAP was used according to routine patient care. This included the use of quantitative bronchoscopic bronchoalveolar lavage cultures to definitively diagnose VAP. RESULTS: A total of 37 episodes of Achromobacter VAP occurred in 34 trauma intensive care unit patients over a 15-year period. The most commonly used definitive antibiotics were imipenem/cilastatin, cefepime, or trimethoprim/sulfamethoxazole. The primary outcome of clinical success was achieved in 32 of 37 episodes (87%). This is similar to previous studies of other NFGNB VAP (eg, Pseudomonas, Acinetobacter) from the study center. Microbiological success was seen in 21 of 28 episodes (75%), and VAP-related mortality was 9% (3 of 34 patients). CONCLUSIONS: Achromobacter is a rare but potentially serious cause of VAP in critically ill patients. In this study, there was an acceptable success rate compared with other causes of NFGNB VAP in this patient population.


Subject(s)
Achromobacter , Anti-Bacterial Agents/therapeutic use , Gram-Negative Bacterial Infections/drug therapy , Pneumonia, Bacterial/drug therapy , Pneumonia, Ventilator-Associated/drug therapy , Adult , Critical Illness/therapy , Female , Humans , Intensive Care Units , Male , Middle Aged , Retrospective Studies
6.
J Vasc Interv Radiol ; 28(9): 1248-1254, 2017 Sep.
Article in English | MEDLINE | ID: mdl-28642012

ABSTRACT

PURPOSE: To evaluate efficacy and safety of a novel device that combines an inferior vena cava (IVC) filter and central venous catheter (CVC) for prevention of pulmonary embolism (PE) in critically ill patients. MATERIALS AND METHODS: In a multicenter, prospective, single-arm clinical trial, the device was inserted at the bedside without fluoroscopy and subsequently retrieved before transfer from the intensive care unit (ICU). The primary efficacy endpoint was freedom from clinically significant PE or fatal PE 72 hours after device removal or discharge, whichever occurred first. Secondary endpoints were incidence of acute proximal deep venous thrombosis (DVT), catheter-related thrombosis, catheter-related bloodstream infections, major bleeding events, and clinically significant thrombus (occupying > 25% of volume of filter) detected by cavography before retrieval. RESULTS: The device was placed in 163 critically ill patients with contraindications to anticoagulation; 151 (93%) were critically ill trauma patients, 129 (85%) had head or spine trauma, and 102 (79%) had intracranial bleeding. The primary efficacy endpoint was achieved for all 163 (100%) patients (95% confidence interval [CI], 97.8%-100%, P < .01). Diagnosis of new or worsening acute proximal DVT was time dependent with 11 (7%) occurring during the first 7 days. There were no (0%) catheter-related bloodstream infections. There were 5 (3.1%) major bleeding events. Significant thrombus in the IVC filter occurred in 14 (8.6%) patients. Prophylactic anticoagulation was not initiated for a mean of 5.5 days ± 4.3 after ICU admission. CONCLUSIONS: This novel device prevented clinically significant and fatal PE among critically ill trauma patients with low risk of complications.


Subject(s)
Central Venous Catheters , Pulmonary Embolism/etiology , Pulmonary Embolism/prevention & control , Vena Cava Filters , Wounds and Injuries/complications , Adult , Central Venous Catheters/adverse effects , Critical Illness , Device Removal , Equipment Safety , Female , Fluoroscopy , Humans , Intensive Care Units , Male , Prospective Studies , Risk Factors , Treatment Outcome , United States , Vena Cava Filters/adverse effects
8.
Ann Pharmacother ; 49(5): 515-22, 2015 May.
Article in English | MEDLINE | ID: mdl-25690904

ABSTRACT

BACKGROUND: Limited data exist on the role of adjunctive intraventricular (IVT) antibiotics for the treatment of central nervous system (CNS) infections in traumatic brain injury (TBI) patients. OBJECTIVE: To evaluate differences in CNS infection cure rates for TBI patients who received adjunctive IVT antibiotics compared with intravenous (IV) antibiotics alone. METHODS: We retrospectively identified patients with TBI and bacterial CNS infections admitted to the trauma intensive care unit (ICU) from 1997 to 2013. Study patients received IV and IVT antibiotics, and control patients received IV antibiotics alone. Clinical and microbiological cure rates were determined from patient records, in addition to ICU and hospital lengths of stay (LOSs), ventilator days, and hospital mortality. RESULTS: A total of 83 patients were enrolled (32 study and 51 control). The duration of IV antibiotics was similar in both groups (10 vs 12 days, P = 0.14), and the study group received IVT antibiotics for a median of 9 days. Microbiological cure rates were 84% and 82% in study and control groups, respectively (P = 0.95). Clinical cure rates were similar at all time points. No significant differences were seen in days of mechanical ventilation, ICU or hospital LOS, or hospital mortality. When only patients with external ventricular drains were compared, cure rates remained similar between groups. CONCLUSIONS: TBI patients with CNS infections had similar microbiological and clinical cure rates whether they were treated with adjunctive IVT antibiotics or IV antibiotics alone. Shorter than recommended durations of antibiotic therapy still resulted in acceptable cure rates and similar clinically relevant outcomes.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Brain Injuries/complications , Central Nervous System Infections/drug therapy , Adult , Brain Injuries/mortality , Case-Control Studies , Central Nervous System Infections/complications , Central Nervous System Infections/mortality , Critical Illness , Female , Hospital Mortality , Humans , Infusions, Intraventricular , Intensive Care Units , Male , Middle Aged , Respiration, Artificial , Retrospective Studies
10.
Am Surg ; 90(5): 1082-1088, 2024 May.
Article in English | MEDLINE | ID: mdl-38297889

ABSTRACT

BACKGROUND: Given the acuity of patients who receive MTPs and the resources they require, MTPs are a compelling target for performance improvement. This study evaluated adherence with our MTP's plasma:red blood cell ratio (FFPR) of 1:2 and platelet:red blood cell ratio (PLTR) of 1:12, to test the hypothesis that ratio adherence is associated with lower inpatient mortality. MATERIALS AND METHODS: The registry of an urban level I trauma center was queried for adult patients who received at least 6 units of packed red blood cells within 4 hours of presentation. Patients were excluded for interfacility transfer, cardiac arrest during the prehospital phase or within one hour of arrival, or for head AIS ≥5. Univariate analysis and multiple logistic regressions were performed to identify variables associated with early transfusion protocol noncompliance and the effect on inpatient mortality. RESULTS: Three hundred and eighty-three patients were included, with mean ISS of 25.9 ± 13.3 and inpatient mortality of 28.5%. Increasing age, ISS, INR, and total units of blood product transfused were associated with increased odds of mortality, while an increase in revised trauma score was associated with a decreased odds ratio of mortality. Achieving our goal ratios were protective against mortality, with OR of .451 (P = .013) and .402 (P=.003), respectively. DISCUSSION: Large proportions of critically injured patients were transfused fewer units of plasma and platelets than our MTP dictated; failure to achieve intended ratios at 4 hours was strongly associated with inpatient mortality. MTP processes and outcomes should be critically assessed on a regular basis as part of a mature performance improvement program to ensure protocol adherence and optimal patient outcome.


Subject(s)
Blood Transfusion , Wounds and Injuries , Adult , Humans , Blood Platelets , Blood Transfusion/methods , Hospital Mortality , Plasma , Retrospective Studies , Trauma Centers , Wounds and Injuries/therapy
11.
Neurosurgery ; 2024 May 20.
Article in English | MEDLINE | ID: mdl-38767366

ABSTRACT

BACKGROUND AND OBJECTIVES: The management of blunt cerebrovascular injuries (BCVIs) remains an important topic within trauma and neurosurgery today. There remains a lack of consensus within the literature and significant variation across institutions. The purpose of this study was to evaluate management of BCVI at a large, tertiary referral trauma center. METHODS: Institutional Review Board approval was obtained to conduct a retrospective review of patients with BCVI at our Level 1 Trauma Center. Computed tomography angiography was used to identify BCVI for each patient. Patient information was collected, and statistical analysis was performed. With the included risk factors for ischemic complications, a novel scoring system based on ischemic risk, the "Memphis Score," was developed and evaluated to grade BCVI. RESULTS: Two hundred seventeen patients with BCVI from July 2020 to August 2022 were identified. The most common mechanism of injury was motor vehicle collision (141, 65.0%). Vertebral arteries were the most common vessel injured (136, 51.1%) with most injuries occurring at a high cervical location (101, 38.0%). Denver Grade 1 injuries (89, 33.5%) and a Memphis Score of 1 were most frequent (172, 64.6%), and initial anticoagulation with heparin drip was initiated 56.7% of the time (123). Endovascular treatment was required in 24 patients (11.1%) and was usually performed in the first 48 hours (15, 62.5%). While Denver Grade (P = .019) and Memphis Score (P < .00001) were significantly higher in those patients undergoing endovascular treatment, only the Memphis Score demonstrated a significant difference between those patients who had stroke or worsening on follow-up imaging and those who did not (P = .0009). CONCLUSION: Although BCVI management has improved since early investigative efforts, institutions must evaluate and share their data to help clarify outcomes. The novel "Memphis Score" presents a standardized framework to communicate ischemic risk and guide management of BCVI.

12.
Ann Pharmacother ; 47(11): 1584-7, 2013 Nov.
Article in English | MEDLINE | ID: mdl-24259594

ABSTRACT

OBJECTIVE: To report the first case of Rhizobium radiobacter bacteremia in a critically ill trauma patient. CASE SUMMARY: A 36-year-old female trauma patient hospitalized at The Regional Medical Center at Memphis developed bacteremia due to Rhizobium radiobacter on hospital day 9. The central line catheter tip culture from the same hospital day was negative. No source for the R radiobacter bacteremia was identified. Empirical and definitive antibiotic therapy consisted of cefepime 2 g intravenously every 8 hours for at total of 8 days. On completion of antibiotics, the patient demonstrated clinical resolution by immediate defervescence and gradual normalization of her white blood cell count. She demonstrated microbiologic success of therapy with negative blood cultures on hospital days 22, 34, 45, and 61. She was discharged on hospital day 80. DISCUSSION: Rhizobium species are common soil and plant pathogens that rarely cause infections in humans. Previous reports of Rhizobium infections have been in immunocompromised patients; generally those with cancer or HIV infection. Intravenous catheters have commonly been cited as the source of infection. The trauma patient in this case constitutes a unique presentation of R radiobacter bacteremia when compared with other case reports. Her indwelling catheter was not the source of her infection, and her only identifiable risk factor for R radiobacter infection was hospitalization. However, she did possess potential reasons for development of an infection with an unusual organism such as R radiobacter. Potential immune modulating therapies included blood transfusions, opioid analgesics, benzodiazepines, general anesthetics, and surgical procedures. Finally, trauma itself has been associated with some degree of immunosuppression. All these issues may have placed the patient in this case at risk of an opportunistic infection like R radiobacter. CONCLUSION: Based on this case, R radiobacter may be considered a potential pathogen causing bacteremia in critically ill trauma patients.


Subject(s)
Agrobacterium tumefaciens/drug effects , Anti-Bacterial Agents/therapeutic use , Bacteremia/drug therapy , Cephalosporins/therapeutic use , Opportunistic Infections/drug therapy , Wounds and Injuries/drug therapy , Adult , Agrobacterium tumefaciens/isolation & purification , Anti-Bacterial Agents/administration & dosage , Bacteremia/blood , Bacteremia/immunology , Bacteremia/microbiology , Cefepime , Cephalosporins/administration & dosage , Critical Illness , Female , Humans , Opportunistic Infections/blood , Opportunistic Infections/immunology , Opportunistic Infections/microbiology , Treatment Outcome , Wounds and Injuries/blood , Wounds and Injuries/immunology , Wounds and Injuries/microbiology
13.
Ann Pharmacother ; 47(12): 1736-9, 2013 Dec.
Article in English | MEDLINE | ID: mdl-24259621

ABSTRACT

OBJECTIVE: To report a case of Chryseobacterium indologenes ventilator-associated pneumonia (VAP) in a critically ill trauma patient. CASE SUMMARY: This report describes a 66-year-old critically ill trauma patient who developed VAP, which was caused by C indologenes. The patient was injured in a riding lawn mower accident that trapped him underwater in a pond. The patient required surgery for intra-abdominal injuries and was mechanically ventilated in the trauma intensive care unit. On hospital day 5, the patient developed signs and symptoms of VAP. A diagnosis of C indologenes VAP was confirmed based on a quantitative culture from a bronchoscopic bronchoalveolar lavage. The patient's infection was successfully treated with moxifloxacin for 2 days followed by cefepime for 7 days. DISCUSSION: Formally known as Flavobacterium indologenes, C indologenes is a Gram-negative bacillus normally found in plants, soil, foodstuffs, and fresh and marine water sources. Recently, worldwide reports of C indologenes infections in humans have been increasing, though reports from the United States are still rare. Bacteremia and pneumonia are the most commonly reported infections, and most patients are immunocompromised. The current case differs from most previous reports because this patient was in the United States and did not have any traditional immunocompromised states (eg, transplant, cancer, HIV/AIDS, or corticosteroid use). CONCLUSION: This case report demonstrates that C indologenes can cause VAP in a trauma ICU patient.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Aza Compounds/therapeutic use , Cephalosporins/therapeutic use , Chryseobacterium , Flavobacteriaceae Infections/drug therapy , Pneumonia, Ventilator-Associated/drug therapy , Quinolines/therapeutic use , Aged , Cefepime , Critical Illness , Flavobacteriaceae Infections/diagnostic imaging , Fluoroquinolones , Humans , Intensive Care Units , Male , Moxifloxacin , Pneumonia, Ventilator-Associated/diagnostic imaging , Radiography , Wounds and Injuries
14.
Trauma Surg Acute Care Open ; 8(Suppl 1): e001142, 2023.
Article in English | MEDLINE | ID: mdl-37082314

ABSTRACT

There are a number of leadership styles. A leader can be loud and boisterous, quiet and unassuming, or anywhere in between. Some are like a chameleon and change their style depending on the circumstances. Regardless of style, there are certain traits that must be present for surgeon-leaders to be effective. Some such traits include strategic thinking, team building, effective communication, accountability, setting clear goals, technical expertise, faculty development, and selflessness. These seven traits can be summed up in two words: Tim Fabian. The following sections will hopefully illustrate Dr Fabian's attributes as they relate to these leadership traits. Some actions will fall under more than one trait.

15.
Wounds ; 35(1): E35-E38, 2023 01.
Article in English | MEDLINE | ID: mdl-36749996

ABSTRACT

INTRODUCTION: A novel BCMH sheet has been shown to achieve improved wound closure rates in chronic and acute wounds when compared with SOC. OBJECTIVE: This retrospective evaluation assessed chronic wound closure rates with SOC or treatment with the BCMH sheet in an urban hospital wound clinic. METHODS: Forty-seven chronic wounds were treated with SOC or the BCMH sheet. The primary endpoint was time to closure. For wounds that did not close, investigations were conducted to determine the reason. RESULTS: Twenty wounds were treated with SOC, which varied in usage of multiple products and/or therapies, and 27 wounds were treated with the BCMH sheet. The average initial wound size was not statistically different between the groups. In both groups, most wounds that were treated did not close. For wounds that did close, the average time to closure was 2x faster in the BCMH group compared with the SOC group (7.4 weeks and 14.8 weeks, respectively; P < .05). CONCLUSIONS: This retrospective evaluation showed average time to wound closure to be significantly faster with BCMH compared with SOC in patients who maintained adherence with regular visits.


Subject(s)
Honey , Wound Healing , Humans , Retrospective Studies , Durapatite , Collagen , Lower Extremity
16.
Crit Care ; 16(5): R193, 2012 Oct 15.
Article in English | MEDLINE | ID: mdl-23068293

ABSTRACT

INTRODUCTION: Limited data suggest mild hypernatremia may be related to lower intracranial pressure (ICP) in patients with traumatic brain injury (TBI). The practice at the study center has been to use hypertonic saline (HTS) to generate a targeted serum sodium of 145 to 155 mEq/l in patients with TBI. The purpose of this study was to determine the relationship between serum sodium values and ICP, and to evaluate the acute effect of HTS on ICP. METHODS: A retrospective review of patients who were admitted to the trauma ICU for TBI, had an ICP monitor placed, and received at least one dose of HTS between January 2006 and March 2011 was performed. Data were collected for up to 120 hours after ICP monitor placement. The primary outcome was the relationship between serum sodium and maximum ICP. Secondary outcomes were the relationship between serum sodium and the mean number of daily interventions for ICP control, and the acute effect of HTS on ICP during the 6 hours after each dose. Linear regression was used to analyze the primary outcome. Analysis of variance on ranks and repeated measures analysis of variance were used to evaluate the number of interventions and the acute effect of HTS on ICP, respectively. RESULTS: Eighty-one patients were enrolled with mean ± standard deviation age of 36 ± 15 years and median Glasgow Coma Scale score of 7 (interquartile range, 4 to 7). A total of 1,230 serum sodium values (range, 118 to 174 mEq/l) and 7,483 ICP values (range, 0 to 159 mmHg) were collected. There was no correlation between serum sodium and maximum ICP (R(2) = 0.0052). The overall mean ± standard deviation number of interventions for elevated ICP per day was 4.2 ± 2.9, 2.9 ± 2.0, and 2.6 ± 2.3 for patients with a mean serum sodium of < 145, 145 to 155, and > 155 mEq/l, respectively (P < 0.001). Regarding the acute effect of HTS on ICP, there was no statistical difference in mean ICP compared with baseline during hours 1 through 6 following HTS doses (baseline, 13.7 ± 8.4 mmHg; hour 1, 13.6 ± 8.3 mmHg; hour 2, 13.5 ± 8.8 mmHg; hour 3, 13.3 ± 8.7 mmHg; hour 4, 13.4 ± 8.7 mmHg; hour 5, 13.4 ± 8.3 mmHg; hour 6, 13.5 ± 8.3 mmHg; P = 0.84). CONCLUSIONS: Serum sodium concentrations did not correlate with ICP values. These results warrant further evaluation and possible reassessment of sodium goals for ICP management in patients with TBI.


Subject(s)
Craniocerebral Trauma/blood , Drug Delivery Systems/methods , Hypernatremia/blood , Intracranial Pressure/physiology , Saline Solution, Hypertonic/administration & dosage , Sodium/blood , Adult , Craniocerebral Trauma/drug therapy , Female , Humans , Hypernatremia/drug therapy , Intracranial Pressure/drug effects , Male , Middle Aged , Retrospective Studies , Treatment Outcome , Young Adult
17.
Adv Surg ; 46: 205-17, 2012.
Article in English | MEDLINE | ID: mdl-22873041

ABSTRACT

BCVI remains a potentially devastating consequence of blunt-force trauma. However, over the past decades significant advances have been made in understanding the pathophysiology, risk factors, and natural history of BCVI. Given the initial asymptomatic period, there is time to diagnose and treat these lesions before the onset of neurologic insult. This early recognition and intervention greatly improves morbidity and mortality directly associated with BCVI. Screening criteria have been identified and reviewed. All patients at risk of BCVI, based on mechanism of injury and risk factors, should be rapidly evaluated for possible injury. It is the authors' current belief that even the newest generation of CT scanners has not been proved to reliably diagnose BCVI. Until further work is done to advance the technology of CTA and prove its equivalence to DSA, there exists too much potential neurologic morbidity and mortality for one to rely on CTA alone (Table 2). Given the variable, and often low, reported sensitivities of CTA, the cost analysis done by Kaye and colleagues [23] would also recommend initial DSA as being cost-effective in avoiding the long-term devastating sequelae of stroke. At the time of writing the authors recommend that CTA be included in an algorithm to evaluate BCVI, but the current data are too disparate with widely variable reported sensitivities, and the risk of missed injury and stroke too severe, to rely on CTA as the definitive diagnostic or screening test for BCVI. Rather, abnormal CTA findings should be added to the traditional screening criteria to identify patients at risk of BCVI; these patients should be evaluated with DSA for definitive screening. Adding abnormal CTA findings to the traditionally described BCVI screening criteria widens the criteria substantially, allowing identification of almost all of the elusive 20% of patients traditionally not identified with basic screening criteria. In addition, given the high specificity of CTA and the decreased morbidity of BCVI with rapid institution of treatment, the authors recommend beginning a low-dose heparin drip (if there are no contraindications to anticoagulation) based on CTA findings while awaiting the confirmatory DSA. Despite advances in CTA technology in recent years, DSA currently remains the gold standard for the diagnosis of BCVI. All patients with standard risk factors for BCVI, or abnormal findings on CTA, should undergo DSA as the screening test of choice for BCVI.


Subject(s)
Carotid Artery Injuries/diagnostic imaging , Head Injuries, Closed/diagnostic imaging , Tomography, X-Ray Computed , Vertebral Artery/injuries , Wounds, Nonpenetrating/diagnostic imaging , Aneurysm, False/diagnostic imaging , Angiography, Digital Subtraction , Carotid Artery, Internal, Dissection/diagnostic imaging , Cerebral Angiography , Emergency Service, Hospital , Humans
18.
Am J Surg ; 224(1 Pt A): 111-115, 2022 07.
Article in English | MEDLINE | ID: mdl-35361470

ABSTRACT

BACKGROUND: The Federal Assault Weapons Ban (FAWB) was in effect from 1994 to 2004. We sought to examine its impact on firearm-related homicides. METHODS: All firearm-related homicides occurring in three metropolitan United States cities were analyzed during the decade preceding (PRE), during (BAN), and after (POST) the FAWB. Files were obtained from the Federal Bureau of Investigation. Rates of firearm-related homicides were stratified by year and compared using simple linear regression. RESULTS: 21,327 firearm-related homicides were analyzed. The median number of firearm-related homicides per year decreased from 333 (PRE) to 199 (BAN) (p = 0.008). This effect persisted following expiration of the ban (BAN 199 vs POST 206, p = 0.429). The rate of firearm-related homicides per 1 M population also decreased from 119.4 in 1985 to 49.2 in 2014 (ß = -2.73, p < 0.0001). CONCLUSIONS: During the FAWB, there was a significant decrease in firearm-related homicides in three of the most dangerous cities, underscoring the need for better directed prevention efforts.


Subject(s)
Firearms , Suicide , Wounds, Gunshot , Homicide , Humans , Linear Models , Records , United States/epidemiology , Wounds, Gunshot/epidemiology , Wounds, Gunshot/prevention & control
19.
J Am Coll Surg ; 234(4): 672-676, 2022 04 01.
Article in English | MEDLINE | ID: mdl-35290287

ABSTRACT

BACKGROUND: Gun violence remains a significant public health problem. Although gun violence prevention efforts mostly target homicides, nationally, two-thirds of all firearm deaths are suicides. The purpose of this study was to define patterns of firearm-related deaths and examine the effect of population size. STUDY DESIGN: All firearm-related deaths in the US between 1999 and 2016 were analyzed. Homicides and suicides were obtained from the Federal Bureau of Investigation and the Centers for Disease Control and Prevention, respectively, comprising the database. For each state, the largest metropolitan city by population and a corresponding small urban city were selected. Firearm-related deaths were stratified by type and city size and compared. Rates of firearm-related homicides and suicides per 1 million population were stratified by year and compared over time using simple linear regression. RESULTS: 544,749 firearm-related deaths occurred across the US over the study period (38% homicides, 62% suicides). The median rate of firearm-related suicides was significantly greater than firearm-related homicides regardless of city size and across the US. Linear regression analysis failed to identify a significant change in the rate of firearm-related homicides over the study period. However, the rate of firearm-related suicides increased significantly regardless of city size between 1999 and 2016. CONCLUSION: Although homicides account for the majority of firearm-related deaths in metropolitan areas, suicides constitute a disproportionate number in smaller urban areas. Although the rate of homicides has stabilized, the rate of firearm-related suicides continues to increase significantly, underscoring the need for better direct prevention efforts and public health policy.


Subject(s)
Firearms , Suicide Prevention , Wounds, Gunshot , Cause of Death , Homicide/prevention & control , Humans , Violence , Wounds, Gunshot/epidemiology , Wounds, Gunshot/prevention & control
20.
Am Surg ; 88(7): 1432-1436, 2022 Jul.
Article in English | MEDLINE | ID: mdl-35404149

ABSTRACT

BACKGROUND: Pelvic fractures are often complicated by hemorrhage contributing to morbidity and mortality. Management of these patients is multifaceted and computed tomography (CT) imaging plays an integral diagnostic role. The purpose of this study was to identify radiographic and clinical predictors of therapeutic angiography in patients with blunt pelvic fractures. METHODS: All patients with blunt pelvic fractures who underwent angiography following admission CT scan were identified over a 6-year period. A radiologist reviewed the CT scans to identify potential predictors of pelvic hemorrhage. Patients were stratified by intervention [therapeutic angiography (TA) vs non-therapeutic angiography (NTA)] and compared. Multivariable logistic regression (MLR) was performed to determine independent predictors of TA. Youden's index was used to identify the optimal value of selected predictors identified on MLR. RESULTS: 177 patients were identified: 42% underwent TA and 58% underwent NTA. Patients undergoing TA were more likely to have a higher injury burden and greater resuscitative transfusion requirements, display both a brighter blush density on arterial phase CT and a larger % change in arterial to venous phase blush density. The optimal arterial blush density was determined to be 250 HU. MLR identified pre-angiography transfusion requirements (OR 1.175; 95% CI 1.054-1.311, P = .0189) and arterial blush density (OR 1.011; 95% CI 1.005-1.016, P < .0001) as independent predictors of therapeutic angiography. CONCLUSION: CT imaging remains vital in assessing patients with pelvic fractures and associated hemorrhage following blunt trauma. For patients requiring multiple resuscitative transfusions with CT findings of an arterial blush measuring ≥250 HU, early angiography should be the preferred approach.


Subject(s)
Embolization, Therapeutic , Fractures, Bone , Pelvic Bones , Angiography , Embolization, Therapeutic/methods , Fractures, Bone/complications , Fractures, Bone/diagnostic imaging , Fractures, Bone/therapy , Hemorrhage/diagnostic imaging , Hemorrhage/etiology , Humans , Pelvic Bones/diagnostic imaging , Pelvic Bones/injuries , Tomography, X-Ray Computed , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL